SCHEMBL24308802

SCHEMBL24308802

CCC(C)N1CCN(CC(O)C(C)C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.36
ATM Q13315 1/20 0.36
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
GPR183 P32249 1/20 0.33
PIK3CD O00329 1/20 0.32
USP2 O75604 1/20 0.32
DRD2 P14416 2/20 0.32
DRD3 P35462 2/20 0.32
SLC18A3 Q16572 1/20 0.32
HRH3 Q9Y5N1 1/20 0.31
ADRA2A P08913 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31
HSD17B10 Q99714 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18704903 0.82 MAPT (0.40) MAPTATMKDM4EMEN1KMT2A
SCHEMBL20349460 0.79 L3MBTL1 (0.40) MAPTATMKDM4EMEN1KMT2A
SCHEMBL20021301 0.79 PIK3CD (0.45) KDM4EMEN1KMT2AGPR183PIK3CD
SCHEMBL21733035 0.79 PIK3CD (0.33) MAPTATMKDM4EMEN1KMT2A
SCHEMBL20328017 0.77 ALDH1A1 (0.43) MAPTATMKDM4EMEN1KMT2A
SCHEMBL11575106 0.76
SCHEMBL15348806 0.76 KDM4E (0.42) KDM4EMEN1KMT2AGPR183HRH3
SCHEMBL16304066 0.75 GAA (0.47) MAPTATMKDM4EMEN1KMT2A
SCHEMBL20088212 0.74 MAPT (0.56) MAPTATMKDM4EMEN1KMT2A
SCHEMBL12850091 0.74 KDM4E (0.37) MAPTKDM4EMEN1KMT2AGPR183

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119396-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119396-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, ROR1 MAPT 1938/4885ATM 685/4885KDM4E 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.